The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > The Canadian Special Access Program

The Canadian Special Access Program

Posted 01 January 2010 | By

In Canada, the marketing of drugs and medical devices requires prior approval by Health Canada, the government department roughly equivalent to the US Department of Health & Human Services. Through a narrow, requestbased regulatory exemption called the Special Access Program, Canadian doctors (and patients) can gain access to otherwise unauthorized drugs and medical devices. This article explains this regulatory mechanism and the procedures involved.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe